title: [Complete remission of multiple brain metastases of non-small cell lung cancer induced by gefitinib monotherapy].
abstract: BACKGROUND
  While the activity of tyrosine kinase inhibitors as the first line treatment for primary tumors in patients with stage IV non-small cell lung cancer and a positive EGF receptor mutation is well known, little data on the efficacy in controlling cerebral metastases are available.
  
  
  RESULTS
  A 43-year-old woman was diagnosed with non-small cell lung cancer with cerebral and hepatic metastases. Emergency radiation therapy was initiated at the time of diagnosis due to superior vena cava syndrome. However, after she failed to respond to this therapy and in light of a positive EGF receptor mutation, gefitinib was added at a dose of 250 mg/day while continuing radiation to the primary lesion and cervical lymph nodes. She showed a rapid clinical and radiologic response with complete remission of the cerebral metastases 6 weeks after starting gefitinib. No severe toxicity was observed.
  
  
  CONCLUSIONS
  This case demonstrates that gefitinib can be given during radiation treatment without significant toxicity. Furthermore, complete remission of cerebral metastases can be achieved with tyrosine kinase inhibitor monotherapy.
authors: Klinik für Hämatologie, Onkologie & Palliativmedizin am Klinikum Bielefeld, Bielefeld, Germany.
authors: Frauke
authors: F
authors: Müller
authors: Hendrik
authors: H
authors: Riesenberg
authors: Peter
authors: P
authors: Hirnle
authors: Hans-Björn
authors: HB
authors: Gehl
authors: Paul
authors: P
authors: Düwel
authors: Martin
authors: M
authors: Görner
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary*; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary*; D016371:Cranial Irradiation; D019008:Drug Resistance, Neoplasm; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008207:Lymphatic Metastasis / Q000473:pathology / Q000532:radiotherapy; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging; D011799:Quinazolines / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib